Atlantic Central Enterprise Ltd. (ALCN) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAtlantic Central Enterprise Ltd. (ALCN) trades at $0.0002. Atlantic Central Enterprise Ltd., through its subsidiary Vista Technologies, Inc., provides photorefractive keratectomy and other laser vision correction facilities and services. Sector: Industrials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for ALCN: ALCN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Atlantic Central Enterprise Ltd. (ALCN) Industrial Operations Profile
Atlantic Central Enterprise Ltd., operating through Vista Technologies, provides laser vision correction services, primarily in the US and Western Europe. As an OTC-listed company in the specialty business services sector, it faces unique challenges related to liquidity and regulatory oversight, while serving a niche market within the healthcare industry.
What Is the Investment Thesis for ALCN?
Atlantic Central Enterprise Ltd. presents a speculative investment opportunity due to its presence in the niche market of laser vision correction services. With a gross margin of 100.0%, the company demonstrates potential profitability, but its market capitalization of $0.00B raises concerns about its financial stability and growth prospects. Key value drivers include the increasing demand for vision correction procedures and the company's ability to maintain its high gross margin. However, the negative beta of -9.94 indicates an inverse correlation with the market, suggesting it may not perform well during economic expansions. The company's OTC listing introduces additional risks related to liquidity and regulatory oversight. Investors should carefully weigh the potential rewards against the significant risks before considering an investment in ALCN.
Based on FMP financials and quantitative analysis
ALCN Key Highlights
Gross Margin of 100.0% indicates strong potential profitability in its service offerings.
- Market Cap of $0.00B signals potential financial instability and limited investor confidence.
- Beta of -9.94 suggests an inverse correlation with the market, potentially underperforming during economic growth.
- Operations primarily in the United States and Western Europe provide access to developed healthcare markets.
- Focus on photorefractive keratectomy and laser vision correction services caters to a specific niche within the healthcare industry.
Who Are ALCN's Competitors?
ALCN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| LICN Lichen International Limited | $0.99 | -1.37% | — | |
| CRE Cre8 Enterprise Limited Class A Ordinary Shares | $2.66 | -1.48% | $5.44M | 63 5-pillar |
| THH TryHard Holdings Limited | $1.44 | -3.99% | $7.51M | — |
| MSGY Masonglory Limited | $5.00 | +13.88% | $7.81M | 33 5-pillar |
| SST System1, Inc. | $2.37 | -3.07% | $24.4M | — |
| ANPA Rich Sparkle Holdings Limited | $1.96 | -0.51% | $29.8M | — |
| NTIP Network-1 Technologies, Inc. | $1.62 | -0.61% | $37.3M | 55 5-pillar |
| OMEX Odyssey Marine Exploration, Inc. | $0.67 | +0.47% | $38.3M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALCN's Key Strengths?
Specialized services in laser vision correction.
- High gross margin of 100.0%.
- Operations in developed markets (US and Western Europe).
- Established subsidiary, Vista Technologies, Inc.
What Are ALCN's Weaknesses?
Market capitalization of $0.00B indicates financial instability.
- Negative beta of -9.94 suggests poor performance during economic growth.
- OTC listing introduces liquidity and regulatory risks.
- Limited information available about the company's current operations.
What Are the Key Risks for ALCN?
Limited liquidity due to OTC Other status may hinder trading activities.
- Lack of financial transparency and disclosure could obscure financial health.
- Competition from established vision care providers may erode market share.
- Changes in healthcare regulations and reimbursement policies could impact revenue.
- Negative beta suggests potential underperformance during economic growth.
What Threats Does ALCN Face?
- Competition from established vision care providers.
- Technological advancements rendering current services obsolete.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns affecting demand for elective procedures.
What Are ALCN's Competitive Advantages?
- Specialized expertise in laser vision correction.
- Established presence in the US and Western European markets.
- Proprietary technology or techniques (if applicable).
- Strong relationships with healthcare providers (if applicable).
What Does ALCN Do?
Atlantic Central Enterprise Ltd., formerly known as Bamburgh Limited, was incorporated in 1996 and is headquartered in Hamilton, Bermuda. The company operates through its subsidiary, Vista Technologies, Inc., focusing on providing photorefractive keratectomy and other laser vision correction facilities and services. These services are primarily offered to the healthcare industry, targeting patients seeking vision correction solutions. The company's operational footprint is mainly concentrated in the United States and western Europe, reflecting its strategic focus on developed markets with established healthcare infrastructures. Since its inception, Atlantic Central Enterprise Ltd. has aimed to carve a niche in the specialty business services sector by offering specialized healthcare services. The company's evolution reflects a commitment to leveraging technological advancements in laser vision correction to meet the demands of a growing market. While the company has maintained a consistent focus on its core business, its ability to navigate the competitive landscape and adapt to changing market dynamics remains crucial for sustained growth and profitability. The company's history includes a name change in 1996, signaling a strategic shift or rebranding effort to align with its business objectives.
What Products and Services Does ALCN Offer?
- Provides photorefractive keratectomy (PRK) services.
- Offers other laser vision correction procedures.
- Operates through its subsidiary, Vista Technologies, Inc.
- Serves the healthcare industry.
- Focuses on vision correction solutions.
- Operates primarily in the United States and western Europe.
How Does ALCN Make Money?
- Generates revenue by providing laser vision correction services.
- Offers these services to patients through healthcare facilities.
- Operates primarily in the US and Western Europe.
- Focuses on photorefractive keratectomy and related procedures.
What Industry Does ALCN Operate In?
Atlantic Central Enterprise Ltd. operates within the specialty business services sector, catering specifically to the healthcare industry with laser vision correction services. The market for laser vision correction is influenced by technological advancements, patient demographics, and regulatory standards. The competitive landscape includes companies offering similar services, as well as broader vision care providers. The industry is subject to ongoing advancements in laser technology and surgical techniques, requiring companies to invest in research and development to remain competitive. The company's success depends on its ability to differentiate its services, maintain high-quality standards, and effectively market its offerings to potential customers.
Who Are ALCN's Key Customers?
- Individuals seeking vision correction.
- Healthcare facilities offering vision correction services.
- Patients in the United States and western Europe.
- Individuals with refractive errors such as myopia, hyperopia, and astigmatism.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Atlantic Central Enterprise Ltd. operates in the Specialty Business Services industry within the Industrials sector. It is headquartered in Hamilton, BM. The company is led by CEO Patrick J. Rooney. ALCN has traded publicly since 2023.
ALCN Financials
ALCN Latest News
No recent news available for ALCN.
ALCN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ALCN.
Price Targets
Wall Street price target analysis for ALCN.
ALCN MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ALCN; grades run from A+ (80-100) to F (below 30).
Leadership: Patrick J. Rooney
CEO
Patrick J. Rooney is the CEO of Atlantic Central Enterprise Ltd. His leadership is crucial for guiding the company's strategic direction and navigating the challenges of the specialty business services sector. Further information is needed to assess his qualifications and experience in the healthcare industry.
Track Record: Due to limited information, Patrick J. Rooney's specific achievements, strategic decisions, and company milestones under his leadership cannot be determined. Assessing his impact on Atlantic Central Enterprise Ltd.'s performance requires access to more detailed information about his tenure and contributions to the company's growth and development.
ALCN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, may not meet minimum financial standards, and are subject to higher risks. Investing in OTC Other securities carries significant risks due to the lack of regulatory oversight and the potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in an OTC Other company.
- OTC Tier: OTC Other
- Limited liquidity due to OTC Other status.
- Lack of financial transparency and disclosure.
- Potential for fraud or manipulation.
- Higher risk of delisting or suspension of trading.
- Limited regulatory oversight and investor protection.
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC Other securities.
- Consult with a financial advisor before making any investment decisions.
- Company has been incorporated since 1996.
- Subsidiary, Vista Technologies, Inc., focuses on a specific healthcare service.
- Operations are primarily in the United States and western Europe.
ALCN Industrials Stock FAQ
What do analysts say about ALCN stock?
As of 2026-03-17, there is no available analyst coverage or consensus for Atlantic Central Enterprise Ltd. (ALCN). This lack of coverage is likely due to its OTC listing and small market capitalization.
What are the main risks for ALCN?
The main risks for Atlantic Central Enterprise Ltd. include its OTC Other listing, which implies limited liquidity and regulatory oversight.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available for this company. OTC listed with shell risk detected.